Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children

This study is treating children and teenagers with newly diagnosed standard-risk acute lymphoblastic leukemia (ALL), which is a cancer of the blood and bone marrow. It follows a treatment protocol designed specifically for lower-risk pediatric patients whose cancer is not showing the most dangerous features. **You may be eligible if...** - Your child is between 1 and 10 years old - Your child has been newly diagnosed with ALL (standard risk as defined by the study) - White blood cell count at diagnosis was below 50,000/uL - There is no cancer spread to the testicles - Kidney and liver function are adequate - The cancer does not have certain high-risk genetic features (such as the Philadelphia chromosome or specific other rearrangements) **You may NOT be eligible if...** - Steroids were given within the past 2 weeks before registration - The ALL has high-risk genetic features (Philadelphia chromosome, certain translocations, or complex chromosomal changes) - The ALL is T-cell type - Your child has Down syndrome, Fanconi anemia, Bloom syndrome, or other inherited bone marrow failure conditions - The leukemia is Burkitt type - Your child has significant heart problems on an ECG Talk to your doctor to see if this trial is right for you.